

Immunization Safety Office Updates

Centers for Disease Control and Prevention

Tom Shimabukuro, MD, MPH, MBA

Immunization Safety Office

Division of Healthcare Quality Promotion,

National Center for Emerging and Zoonotic Infectious Diseases

Centers for Disease Control and Prevention (CDC)

Advisory Commission on Childhood Vaccines (ACCV)

June 14, 2012



Topics

- ❑ **1st National Immunization Conference Online (NICO), Vaccine safety session “What’s New in Vaccine Safety?” (March 28, 2012)**
- ❑ **June 2012 Advisory Committee on Immunization Practices (ACIP) meeting preview (June 20-21, 2012)**
- ❑ **Selected recent publications**

1st National Immunization Conference Online

□ Session 8: “What’s New in Vaccine Safety?” (March 28, 2012)

- Presentations and audio available at <https://cdc.confex.com/cdc/nic2012/webprogram/Session12998.html>
 - Immunization Errors (Oops) Reported to the Vaccine Adverse Event Reporting System (B. Hibbs)
 - Updating the Vaccine Injury Table Based On the Institute of Medicine's Report On the Adverse Effects of Vaccines (R. Johann-Liang)
 - HPV Vaccine Safety Review, What Providers Need to Know (J. Gee)

June 2012 ACIP meeting preview

□ Preliminary agenda available online*

- Influenza vaccine safety update during the Influenza session
- Update on development and use of Grading of Recommendations, Assessment, Development and Evaluation (GRADE)
- Update on report from the IOM Committee on Identifying and Prioritizing New Vaccines for Development
 - Ranking Vaccines: A Prioritization Framework - Phase I: Demonstration of Concept and a Software Blueprint†
- Scheduled votes
 - Recommendations for PCV13 use among immunocompromised adults
 - Recommendations for influenza vaccine use for 2012-13

*<http://www.cdc.gov/vaccines/recs/acip/downloads/agenda-2012-06.pdf>

†<http://www.iom.edu/Reports/2012/Ranking-Vaccines-A-Prioritization-Framework-Phase-I.aspx>

Selected publications

- ❑ Greene et al. Risk of Confirmed Guillain-Barre Syndrome Following Receipt of Monovalent Inactivated Influenza A (H1N1) and Seasonal Influenza Vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J Epidemiol. 2012 May 11. [Epub ahead of print]
 - Found a statistically significant elevated risk of GBS following inactivated H1N1 vaccine in self-controlled analysis (relative risk 4.4), but not in the case-centered analysis

- ❑ Tokars et al. The Risk of Guillain-Barré Syndrome Associated with Influenza A (H1N1) 2009 Monovalent Vaccine and 2009-2010 Seasonal Influenza Vaccines: Results from Self-Controlled Analyses. Pharmacoepidemiol Drug Saf. 2012 May;21(5):546-52.
 - Risk of GBS following inactivated H1N1 vaccine was similar to that of some previous formulations of seasonal influenza vaccine (about 1 to 2 cases per million doses administered), suggesting a low risk of GBS following the H1N1 vaccine that is not clearly higher than that of seasonal influenza vaccines

Selected publications

- ❑ **Wise et al. Guillain-Barré Syndrome During the 2009–2010 H1N1 Influenza Vaccination Campaign: Population-based Surveillance Among 45 Million Americans. Am J Epidemiol. 2012 May 11. [Epub ahead of print]**
 - **Risk of GBS following inactivated H1N1 vaccine was much smaller than that observed during the 1976 vaccine campaign and was comparable to some previous seasonal influenza vaccine risk assessments**

Selected publications

- ❑ Klein et al. Measles-Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years. *Pediatrics*. 2012 May;129(5):809-14.
 - MMRV and MMR + V were not associated with increased risk of febrile seizures among 4- to 6-year-olds

- ❑ Moro et al. Postlicensure Safety Surveillance for High-Dose Trivalent Inactivated Influenza Vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010–31 December 2010. *Clin Infect Dis*. 2012 Jun;54(11):1608-14.
 - During the first year after US licensure, no new serious safety concerns were identified in VAERS



Centers for Disease Control and Prevention Atlanta, GA

National Center for Emerging and Zoonotic Infectious Diseases
Division of Healthcare Quality Promotion – Immunization Safety Office



Thank You

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov

Web: www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.